Lpl Financial LLC Supernus Pharmaceuticals, Inc. Transaction History

Lpl Financial LLC

  • $320 Billion
  • Q3 2025

A detailed history of Lpl Financial LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Lpl Financial LLC holds 7,212 shares of SUPN stock, worth $324,540. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,212
Previous 16,482 56.24%
Holding current value
$324,540
Previous $519,000 33.72%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025
SELL
$31.45 - $47.79 $291,541 - $443,013
-9,270 Reduced 56.24%
7,212 $344,000
Q2 2025

Aug 12, 2025
BUY
$30.29 - $33.43 $12,994 - $14,341
429 Added 2.67%
16,482 $519,000
Q1 2025

May 07, 2025
BUY
$31.17 - $40.0 $103,235 - $132,480
3,312 Added 25.99%
16,053 $525,000
Q4 2024

Feb 11, 2025
BUY
$31.89 - $37.83 $64,704 - $76,757
2,029 Added 18.94%
12,741 $460,000
Q3 2024

Nov 08, 2024
BUY
$25.77 - $35.16 $14,225 - $19,408
552 Added 5.43%
10,712 $334,000
Q2 2024

Aug 07, 2024
BUY
$25.99 - $33.85 $71,186 - $92,715
2,739 Added 36.91%
10,160 $271,000
Q1 2024

May 10, 2024
BUY
$27.11 - $35.17 $201,183 - $260,996
7,421 New
7,421 $253,000
Q2 2023

Jul 31, 2023
SELL
$29.91 - $38.73 $37,477 - $48,528
-1,253 Reduced 14.47%
7,406 $222,000
Q1 2023

May 10, 2023
SELL
$34.93 - $42.03 $27,769 - $33,413
-795 Reduced 8.41%
8,659 $313,000
Q4 2022

Feb 07, 2023
SELL
$31.09 - $37.88 $294,546 - $358,875
-9,474 Reduced 50.05%
9,454 $337,000
Q3 2022

Nov 14, 2022
SELL
$28.79 - $35.41 $132,174 - $162,567
-4,591 Reduced 19.52%
18,928 $641,000
Q2 2022

Aug 12, 2022
BUY
$25.33 - $34.25 $47,696 - $64,492
1,883 Added 8.7%
23,519 $680,000
Q1 2022

May 16, 2022
BUY
$28.51 - $32.9 $1,824 - $2,105
64 Added 0.3%
21,636 $699,000
Q4 2021

Feb 14, 2022
BUY
$26.37 - $34.22 $46,252 - $60,021
1,754 Added 8.85%
21,572 $629,000
Q3 2021

Nov 15, 2021
BUY
$23.54 - $31.39 $32,249 - $43,004
1,370 Added 7.43%
19,818 $529,000
Q2 2021

Aug 13, 2021
SELL
$26.72 - $33.19 $63,353 - $78,693
-2,371 Reduced 11.39%
18,448 $568,000
Q1 2021

May 14, 2021
BUY
$24.15 - $31.45 $93,557 - $121,837
3,874 Added 22.86%
20,819 $545,000
Q4 2020

Feb 12, 2021
BUY
$17.7 - $25.81 $21,098 - $30,765
1,192 Added 7.57%
16,945 $426,000
Q3 2020

Nov 09, 2020
SELL
$20.2 - $25.05 $2,565 - $3,181
-127 Reduced 0.8%
15,753 $328,000
Q2 2020

Aug 13, 2020
BUY
$17.09 - $24.89 $12,168 - $17,721
712 Added 4.69%
15,880 $377,000
Q1 2020

May 14, 2020
SELL
$14.45 - $24.69 $5,823 - $9,950
-403 Reduced 2.59%
15,168 $273,000
Q4 2019

Feb 14, 2020
SELL
$19.93 - $29.13 $1,953 - $2,854
-98 Reduced 0.63%
15,571 $369,000
Q3 2019

Nov 13, 2019
SELL
$25.47 - $33.37 $3,260 - $4,271
-128 Reduced 0.81%
15,669 $431,000
Q2 2019

Aug 09, 2019
SELL
$29.96 - $38.87 $262,060 - $339,995
-8,747 Reduced 35.64%
15,797 $523,000
Q1 2019

May 08, 2019
SELL
$32.77 - $41.99 $93,394 - $119,671
-2,850 Reduced 10.4%
24,544 $860,000
Q4 2018

Feb 07, 2019
BUY
$30.84 - $49.51 $53,630 - $86,097
1,739 Added 6.78%
27,394 $910,000
Q3 2018

Nov 14, 2018
SELL
$42.7 - $56.55 $802,760 - $1.06 Million
-18,800 Reduced 42.29%
25,655 $1.29 Million
Q2 2018

Aug 14, 2018
BUY
$44.1 - $59.85 $1.08 Million - $1.46 Million
24,437 Added 122.08%
44,455 $2.66 Million
Q1 2018

May 15, 2018
SELL
$37.15 - $46.9 $41,199 - $52,012
-1,109 Reduced 5.25%
20,018 $917,000
Q4 2017

Feb 14, 2018
SELL
$36.4 - $42.6 $48,230 - $56,445
-1,325 Reduced 5.9%
21,127 $842,000
Q3 2017

Nov 14, 2017
BUY
$36.75 - $49.65 $84,451 - $114,095
2,298 Added 11.4%
22,452 $898,000
Q2 2017

Aug 14, 2017
BUY
N/A
20,154
20,154 $869,000

Others Institutions Holding SUPN

# of Institutions
330
Shares Held
60.2M
Call Options Held
234K
Put Options Held
0
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.41B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email